Authors: Xin Hui S Chan, Ilsa L Haeusler, Bennett J K Choy, Md Zakiul Hassan, Junko Takata, Tara P Hurst, Luke M Jones, Shanghavie Loganathan, Elinor Harriss, Jake Dunning, Joel Tarning, Miles W Carroll, Peter W Horby, Piero L Olliaro
Year: 2024
Journal: Review
DOI: 10.xxxx/xxxxx
Summary#
This paper reviews the safety and efficacy of therapeutic options for Nipah virus disease to prioritize drug candidates for further evaluation in clinical trials, suggesting trialling 1F5, m102.4, and remdesivir (alone or in combination) for prophylaxis and early treatment.
Key Findings#
- Trialling 1F5, m102.4, and remdesivir for prophylaxis and early treatment of Nipah virus disease
- Well designed clinical efficacy trials and in-vivo pharmacokinetic–pharmacodynamic studies needed to optimise therapeutic candidates
Methodology#
- Study Type: Review
- Sample Size: Not specified
- Geographic Focus: Malaysia, Singapore, Bangladesh, India
- Time Period: 1998-present
Topics#
Therapeutics, Nipah virus disease
Relevance#
The paper discusses the urgent need for approved therapeutics or vaccines to treat Nipah virus disease due to its high case-fatality rate and potential for a pandemic.